BSEOthers5h ago · 22 Jul 2026, 01:44 pm

Compliance - 57(4)

Transgene Biotek Ltd · 526139

✦ AI Summary

Transgene Biotek Ltd has informed that Regulation 57 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the company as there are no non-convertible securities with interest/dividend/principal payable during the quarter ended 30.06.2026.

Analysis Scores

Earnings Impact5/10

Growth Catalyst2/10

Governance Concern1/10

Regulatory Risk1/10

Balance Sheet Risk1/10

Liquidity Impact5/10

Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

Full Announcement

Transgene Biotek Ltd - 526139 - Compliance-57 (4) : Prior intimation to the beginning of the quarter

Attachments (1)

📄

c85a3764-8cef-4ed5-8811-1f9811beafdf.pdf

pdf

Download →

View document text

Date 22-07-2026 The General Manager Department of Corporate Services – CRD BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street,Mumbai 400 001. Subject: Compliance under regulation 57 of SEBI '(Listing Obligations And Disclosure Requirements) Regulations, 2015 for the quarter ended 30.06.2026 We wish to inform that Regulation 57 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to our company since there is no non convertible securities for which interest / dividend / principal is payable during the quarter. We kindly request you to take the above said on record. Thanking You, Yours faithfully For TRANSGENE BIOTEK LIMITED DR K KOTESWARA RAO CHAIRMAN & MANAGING DIRECTOR Plot 69 & 70IDA Bollaram, Sangareddy District–502 325, Telangana, India Ph: +91-40-65589499 Fax: +91-8458-279755 Web:www.transgenebiotek.com Email:info@transgenebiotek.com, CIN No: L85195AP1990PLC011065